Table 2.
Galectin-1 on immune cells in the tumor microenvironment. OS, overall survival.
| Organ/Tumor | Role | Benefit | Prognostic Marker | References | |
|---|---|---|---|---|---|
| Glioma | Increased in glioma cell, not in host cells | NK immunossurveillance, increase OS | [28,85] | ||
| Head and neck squamous cervical cancer | HNSCC | Decreases CD27/CD28 | Inversely correlated to OS | [37] | |
| Head and neck squamous cervical cancer | HNSCC | Decreases IFN-γ production | Inversely correlated to OS | Poor prognostic | [51,68] |
| Hepatocellular carcinoma | HCC | Inhibition of T cell function | [73] | ||
| Lymphoma (cutaneous T-cell) | Th2 differentiation | [75] | |||
| Pancreatic ductal adenocarcinoma | PDA | Angiogenesis inductor | T-cell infiltration | [50] | |
| Prostate cancer | PCa | Promotes angiogenesis when expressed by tumor cells; enhances immune evasion when expressed by T cells (esp. CD8+ T cells) | Yes | [53,86] |